Evaluating the effectiveness of rimegepant for treating migraines

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness and tolerability of rimegepant, a new oral medication, for treating acute migraine attacks in patients with episodic or chronic migraines. Participants will take rimegepant during their next migraine attack, and data will be collected on its effectiveness and side effects over at least four migraine episodes and a follow-up period of three months. The study is designed to reflect real-world usage and outcomes, building on previous clinical trial findings that indicated rimegepant's efficacy and tolerability.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).
* At least 3 MMDs
* Good compliance to study procedures
* Availability of headache diary at least of the preceding months before enrollment

Exclusion Criteria:

* Subjects with contraindications for use of gepants;
* Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
* medical comorbidities that could interfere with study results;
* Pregnancy and breastfeeding.

Where it's running

• SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
  Florence, Italy Recruiting
• IRCCS National Neurological Institute "C. Mondino" Foundation
  Pavia, Italy Recruiting

Study contacts

• Study coordinator: Luigi F Iannone, MD
• Email: luigifrancesco.iannone@unifi.it
• Phone: +393896969606

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing telehealth cognitive behavioral therapy for youth with migraines

  This study is testing whether online therapy for kids and teens with migraines works better when combined with medication or on its own.

  Recruiting at 15 sites Children's Hospital Medical Center, Cincinnati · Birmingham, Alabama and 14 other locations · NCT05889624

• Gepants for Acute Migraine in the Emergency Department

  This study tests whether rimegepant or zavegepant given in the ED can relieve an acute migraine for adults.

  Recruiting Phase 1 University of South Florida · Tampa, Florida · NCT07667621

• Analyzing CGRP Levels in Migraine Patients by Age and Sex

  This study looks at the levels of a substance linked to migraines in people with migraines and healthy individuals to see how age and sex might affect treatment responses.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT06674772

• Evaluating the effectiveness of rimegepant for preventing migraines

  This study is testing if taking a new migraine medication called rimegepant every other day can help people with frequent or chronic migraines feel better over two years.

  Recruiting at 2 sites University of Florence · Florence, Florence and 1 other locations · NCT06409832

• Evaluating migraine treatment effects using different designs

  This study is testing how different ways of giving treatment information affect the effectiveness of a migraine medication compared to a placebo in people with episodic migraines.

  Recruiting University of Aarhus · Aarhus C and 1 other locations · NCT06617832

• Assessing the safety and effectiveness of Atogepant for migraine prevention in Korean adults

  This study is testing how well and safely Atogepant works for preventing migraines in Korean adults who have chronic or episodic migraines.

  Recruiting at 36 sites AbbVie · Busan, Busan Gwang Yeogsi and 35 other locations · NCT06603558

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.